Latest News
Updates from NSG Ventures
-
Senti Bio Reports Updated Phase 1 Results: 5 of 7 Patients Achieving Responses, 4 MRD-Negative Complete Remissions, and No Dose-Limiting Toxicities with SENTI-20228AprNews2025 -
Senti Bio delivers exciting initial Phase 1 data for SENTI-202, with 2 of 3 patients achieving MRD-negative complete remission and all patients showing a well-tolerated safety profile2DecNews2024
-
Medical AI provider Lunit raises $61M in funding round led by major global healthcare investors25NovNews2021
